TG Therapeutics secured a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital. The facility materially bolsters the company's liquidity and extends its runway, reducing near-term refinancing risk. As secured debt for a commercial-stage biotech, it should support ongoing operations and development plans.
TG Therapeutics secured a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital. The facility materially bolsters the company's liquidity and extends its runway, reducing near-term refinancing risk. As secured debt for a commercial-stage biotech, it should support ongoing operations and development plans.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
